Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alexia Hervieu
Observed names:
A. Hervieu,
A.H. Hervieu
Institution:
Institute of Cancer Research
Observed institutions:
Institute of Cancer Research,
Inserm,
Queen Mary University of London,
Cancer Research UK,
Université Paris Diderot,
Institut polytechnique LaSalle Beauvais,
Barts Cancer Institute
show all 7
ORCID:
0000-0002-8061-6678
Observed ORCID:
0000-0002-8061-6678
OpenAlex ID:
A5081933271
Correction: Corrigendum: Beta 1-integrin–c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes
2016
·
Rachel Barrow-McGee
, Naoki Kishi
, et al.
·
Nature Communications
·
142
PDF
Beta 1-integrin–c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes
2016
·
Rachel Barrow-McGee
, Naoki Kishi
, et al.
·
Nature Communications
·
126
PDF
De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder
2019
·
Eduardo Calpena
, Alexia Hervieu
, et al.
·
The American Journal of Human Genetics
·
72
PDF
The Role of PI3K in Met Driven Cancer: A Recap
2018
·
Alexia Hervieu
, Stéphanie Kermorgant
·
Frontiers in Molecular Biosciences
·
52
PDF
The thermolysin-like metalloproteinase and virulence factor LasB from pathogenic Pseudomonas aeruginosa induces anoikis of human vascular cells
2011
·
Nathalie Beaufort
, Elisabeth Corvazier
, et al.
·
Cellular Microbiology
·
42
A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration
2020
·
Alexia Hervieu
, Sara Farrah Heuss
, et al.
·
Science Signaling
·
29
Front face fluorescence spectroscopy and multiway analysis for process control and NFC prediction in industrially processed cookies
2008
·
Jad Rizkallah
, Francisco J. Morales
, et al.
·
Chemometrics and Intelligent Laboratory Systems
·
23
R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancers
2026
·
Chi Zhang
, Yu-jing Lu
, et al.
·
Nature Communications
·
8
Native Size-Exclusion Chromatography–Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global Changes
2022
·
Rahul S. Samant
, Silvia Batista
, et al.
·
Molecular & Cellular Proteomics
·
8
PDF
Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
·
Cancer Discovery
·
3
PDF
Abstract 6011: Pharmacological inhibition of PMS2 increases tumor mutational burden, induces microsatellite instability and elicits immune mediated rejection in vivo
2024
·
Eleonora Piumatti
, Alexia Hervieu
, et al.
·
Cancer Research
·
3
Unconventional role of RAC1 in MET-driven anchorage-independent tumor growth
2020
·
Alexia Hervieu
, Stéphanie Kermorgant
·
Molecular & Cellular Oncology
·
3
PDF
Abstract C086: NP1867, a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2, functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples
2023
·
Julian Blagg
, Philippe Riou
, et al.
·
Molecular Cancer Therapeutics
·
1
Supplementary Methods 1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Resources Table 1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Table 3 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Figure S6 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Figure S1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Figure S9 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Figure S7 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Figure S5 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Figure S3 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Figure S8 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Table 1 and 2 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Supplementary Video 1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
2026
·
Julian Blagg
, Philippe Riou
, et al.
Show more works
View as search
Works count:
32
Citation count:
512
H-index:
8
I10-index:
7
Year
Topic
Type